News | May 15, 2013

Three Key Questions on Breast-Specific Gamma Imaging for Breast Cancer

Report looks at sensitivity of BSGI for screening and diagnosis of breast cancer

May 15, 2013 — ECRI Institute released a report listing three key questions and the answers concerning breast-specific gamma imaging (BSGI; sometimes referred to as molecular breast imaging or MBI). The technology uses a specially designed gamma camera system to image the uptake of a tracer that emits gamma radiation (most commonly 99mtechnetium-sestamibi [MIBI]). MIBI is preferentially taken up by cancer tissue, and thus BSGI can be used to image breast cancer for a variety of clinical indications. Unlike X-ray mammography, BSGI is not affected by the density of breast tissue, and therefore it may be particularly useful for screening and diagnosis of breast cancer in women with dense breast tissue.

Indications for BSGI may include patients with dense breast tissue, difficult-to-interpret mammograms, implants, palpable lesions not detected by mammography, multiple suspicious or indeterminate lesions, pre-biopsy evaluation of suspect areas, disease staging for breast conservation surgery, and evaluation of post-surgical or post-therapeutic breasts. Contraindications are pregnancy and hypersensitivity to the tracer.

Regulatory Status
All three of the BSGI devices manufactured by Dilon Technologies (Newport News, Va.), Gamma Medica (Northridge, Calif.) and GE Healthcare (Wauwatosa, Wis.) have been cleared by the U.S. Food and Drug Administration (FDA) for marketing under the 510(k) process for diagnostic imaging of the breast as an adjunct to mammography.

State of the Evidence Base
ECRI searched 17 external and internal databases, including PubMed and Embase, through Nov. 7, 2012, for clinical trials on the use of BSGI for breast cancer.

Key Question 1: For what indications and patient populations has BSGI been clinically studied?
ECRI identified published studies of BSGI for screening asymptomatic women, for diagnostic workup, for pretreatment evaluation and for monitoring response to neoadjuvant therapy. They did not identify any published studies of BSGI for monitoring response to post-surgical treatment or for detecting recurrences of cancer.

Key Question 2: What is the accuracy of low-dose BSGI for screening the general population? For screening women with dense breast tissue?
Searches did not identify any studies of low-dose BSGI for screening that met our study inclusion criteria.

Key Question 3: What is the accuracy and utility of BSGI for pre-treatment workup? In comparison to other imaging technologies (such as MRI) for this indication?
Four studies of a total of 445 patients met inclusion criteria for analysis for this question. The crude mean diagnostic yields of occult lesions could be computed from the reported data. They rated the evidence as moderate in quality, but no robust analysis could be performed, and therefore they rated the evidence as insufficient to answer this question. Only one study reported on a direct comparison to MRI. Two studies reported information on the impact of BSGI on medical decision making; the most common impact was triggering additional imaging and biopsies, followed by changes to additional treatment plans or leading to more extensive surgical treatment.                               

ECRI Institute Conclusions
For diagnostic workup, the sensitivity of BSGI for distinguishing between malignant and benign lesions is approximately 92 percent. BSGI may be a valid option for a diagnostic workup in some women, particularly for women with dense breast tissue. However, the evidence available as of November 2012 was insufficient to evaluate the accuracy and utility of BSGI for any other breast screening, diagnostic, or monitoring applications.

For more information: www.ecri.org 

Related Content

QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018
News | Ultrasound Women's Health | November 19, 2018
QView Medical will showcase QVCAD, the first U.S. Food and Drug Administration (FDA)-approved artificial intelligence (...
Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
Breast Density Advocate Nancy M. Cappello Passes Away

Nancy Cappello. Image courtesy of AreYouDense.org.

News | Breast Density | November 15, 2018 | Jeff Zagoudis, Associate Editor
Imaging Technology News extends its condolences to the family, friends and colleagues of Nancy M. Cappello, Ph.D., who...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery.
News | Breast Imaging | November 08, 2018
KUBTEC announced the launch of a new innovation in the treatment of breast cancer. The Mozart Supra Specimen...